Nasdaq (NDAQ) Q1 2026 Earnings Transcript

Nasdaq posted a strong Q1 with net revenue up 13% to $1.4 billion, operating income up 17% to $799 million, and diluted EPS up 21% to $0.96, while raising full-year non-GAAP expense guidance to $2.485 billion-$2.545 billion. Financial Technology was a standout, with revenue up 18%, ARR up 16%, and ACV bookings growing more than 50%, supported by cloud-based and AI-driven demand. The company also lifted its dividend to $0.31 per share, repurchased $548 million of stock, and highlighted regulatory progress on 23/5 trading and tokenized securities.

Analysis

The core setup is not just earnings momentum; it is a re-rate story around Nasdaq’s conversion from a cyclical market-structure franchise into a broader compounder with recurring software, data, and regulatory workflows. The biggest second-order effect is that higher 23/5 trading, tokenization, and AI adoption all widen the addressable market for its software stack, not just its exchange volumes, which should support a higher quality multiple even if the listing cycle stays uneven.

The near-term risk is that investors over-earnings-ify the print and underweight the fact that some of the beat came from timing, mix, and one-offs in capital markets technology. If IPO windows stay choppy and volume capture keeps drifting lower as retail activity shifts to lower-priced contracts, the market-services and index franchises can still look “good” while decelerating at the margin. That makes the next two quarters more about guidance credibility than headline growth.

The most interesting long-only angle is the barbell between Nasdaq and the ecosystem beneficiaries: BlackRock, State Street, and FIS all gain distribution or product adjacency, but Nasdaq likely keeps the pricing power because the partners are buying access, not ownership of the economics. The contrarian miss is that the market may be too focused on AI as a cost-saver and not enough on AI as a sales enabler inside regulated workflows; that matters because these products are embedded into renewal cycles, which can sustain revenue even in softer capital markets.

From a catalyst standpoint, the December 23/5 launch and any early tokenization test trades are the cleanest narrative accelerants, while the main failure mode is implementation slippage or slower-than-expected liquidity uptake. In the next 3-6 months, the stock likely trades on whether ARR inflects into the second half as enterprise implementations convert, not on whether another quarter beats by a few cents.

Key Decisions for Investors

• Long NDAQ vs short CME for 3-6 months: NDAQ has more visible software/AI monetization and regulatory workflow expansion; CME is cleaner on pure trading volume but less exposed to recurring technology re-rating. Risk: if macro volatility stays elevated, CME can outperform on transaction leverage.
• Buy NDAQ on any 3-5% post-print pullback, targeting a 6-9 month hold: the setup is for multiple expansion as 23/5 and tokenization become tangible milestones. Risk/reward skews favorably if the market continues to pay up for recurring revenue plus capital returns.
• Pair long NDAQ / short a basket of exchange-adjacent laggards with weaker software mix exposure, such as ICE on a relative basis, over 6 months: Nasdaq has more embedded AI and cloud conversion in fintech; risk is ICE’s more diversified asset-services mix.
• Own BLK and STT tactically alongside NDAQ into the next ETF flow window: they are distribution beneficiaries of Nasdaq-100 expansion, but NDAQ should retain the economics. Timeframe: 1-2 quarters; risk is that flow benefits are slower to show up than expected.
• Optionality trade: NDAQ calls or call spreads into the 23/5 launch date, structured for upside if the market re-prices the platform story ahead of December. Use a spread to limit theta risk; the main risk is a long lag between announcement and monetization.